Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab A/S    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The group usually releases upbeat results with huge surprise rates.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
  • Based on current prices, the company has particularly high valuation levels.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 76.84 times its estimated earnings per share for the ongoing year.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
GENMAB A/S-1.45%13 229
GILEAD SCIENCES19.62%94 124
VERTEX PHARMACEUTICALS16.60%61 693
REGENERON PHARMACEUTICALS34.30%53 154
WUXI APPTEC CO., LTD.-0.12%21 017
BIONTECH SE55.64%13 733
-
BEIGENE, LTD.-12.97%9 553
HUALAN BIOLOGICAL ENGINEERI..-0.87%9 494
NEUROCRINE BIOSCIENCES, INC..-15.14%7 988
SAREPTA THERAPEUTICS, INC.-21.68%7 608
ARGENX SE-10.86%5 784
ASCENDIS PHARMA A/S-14.94%5 376
EXELIXIS, INC.0.28%5 259
REATA PHARMACEUTICALS, INC.-32.35%4 796
ACCELERON PHARMA INC.64.49%4 793
FORTY SEVEN, INC.142.60%4 595
More Results
Financials (DKK)
Sales 2020 5 211 M
EBIT 2020 1 303 M
Net income 2020 1 115 M
Finance 2020 12 793 M
Yield 2020 -
P/E ratio 2020 76,8x
P/E ratio 2021 37,2x
EV / Sales2020 14,8x
EV / Sales2021 10,5x
Capitalization 89 959 M
Upcoming event on GENMAB A/S
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes